AVTX
insider transactionsAvalo Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 30d
-679
0 buy · 679 sell
Net value · 30d
-$10.9K
$0 in · $10.9K out
Sentiment · 30d
Net selling
0% buying · 100% selling
Open-market trades · 30d
1
0 buy · 679 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Other·F
Chief Strategy Officer
$7.7K
588 sh · $13.10
Own -1%
-
Other·F
Chief Medical Officer
$14.2K
1.1K sh · $13.10
Own -2%
-
Other·F
Chief Financial Officer
$1.8K
138 sh · $13.10
Own -0%
-
Other·F
Chief Legal Officer
$14.2K
1.1K sh · $13.10
Own -3%
-
Grant·A
Director
$0
20.1K sh
Own New
-
Grant·A
Director
$0
20.1K sh
Own New
-
Grant·A
Director
$0
20.1K sh
Own New
-
Grant·A
Director
$0
20.1K sh
Own New
-
Grant·A
Director
$0
29.5K sh
Own New
-
Grant·A
Director
$0
20.1K sh
Own New
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
679 sh
Own +1%
-
Sell·S
Chief Medical Officer · 10b5-1
$10.9K
679 sh · $16.00
Own -1%
-
Exercise·M
Chief Medical Officer · 10b5-1
$5.5K
679 sh · $8.04
Own +1%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 10, 2026 | Jennifer Riley | Other F | 588 | $7.7K |
| Jun 10, 2026 | Mittie Doyle | Other F | 1.1K | $14.2K |
| Jun 10, 2026 | Christopher Ryan Sullivan KEY | Other F | 138 | $1.8K |
| Jun 10, 2026 | Paul Varki | Other F | 1.1K | $14.2K |
| Jun 2, 2026 | Samantha Truex | Grant A | 20.1K | $0 |
| Jun 2, 2026 | Aaron Kantoff | Grant A | 20.1K | $0 |
| Jun 2, 2026 | Rita Jain | Grant A | 20.1K | $0 |
| Jun 2, 2026 | Kevin Robert Lind | Grant A | 20.1K | $0 |
| Jun 2, 2026 | Michael Thomas Heffernan | Grant A | 29.5K | $0 |
| Jun 2, 2026 | Gilla Kaplan | Grant A | 20.1K | $0 |
| May 28, 2026 | Mittie Doyle 10b5-1 | Exercise M | 679 | $0 |
| May 28, 2026 | Mittie Doyle 10b5-1 | Sell S | 679 | $10.9K |
| May 28, 2026 | Mittie Doyle 10b5-1 | Exercise M | 679 | $5.5K |
About AVTX insider trading
This page tracks insider transactions for Avalo Therapeutics, Inc. (AVTX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.